Gastrointestinal toxicity of gemtuzumab ozogamicin: real-life data from the AMLCG, SAL, and CELL study groups
TO THE EDITOR:The CD33-directed antibody-drug-conjugate “gemtuzumab ozogamicin” (GO) in combination with the 7+3 standard regimen is currently approved for the treatment of CD33+ acute myeloid leukemia (AML). Although the pivotal ALFA-0701 study did not show a significantly increased toxicity using...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) Editorial |
| Sprache: | Englisch |
| Veröffentlicht: |
July 8 2025
|
| In: |
Blood advances
Year: 2025, Jahrgang: 9, Heft: 13, Pages: 3336-3339 |
| ISSN: | 2473-9537 |
| DOI: | 10.1182/bloodadvances.2024014570 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/bloodadvances.2024014570
|
| Verfasserangaben: | Ricarda Knabe, Philippe Muller, Christoph Schliemann, Maher Hanoun, Julia Marie Unglaub, Barbora Weinbergerová, Jiří Mayer, Carolin Krekeler, Stefan W. Krause, Martin Kaufmann, Sabrina Kraus, Björn Steffen, Franziska Modemann, Marion Subklewe, Veit Bücklein, Wolfgang G. Kunz, Martina Rudelius, Michael von Bergwelt-Baildon, Katja Gutmair, Eva Hoster, Tobias Herold, Christoph Röllig, and Karsten Spiekermann |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1942596251 | ||
| 003 | DE-627 | ||
| 005 | 20251126125906.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 251126s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/bloodadvances.2024014570 |2 doi | |
| 035 | |a (DE-627)1942596251 | ||
| 035 | |a (DE-599)KXP1942596251 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Knabe, Ricarda |e VerfasserIn |0 (DE-588)1382726112 |0 (DE-627)1942596502 |4 aut | |
| 245 | 1 | 0 | |a Gastrointestinal toxicity of gemtuzumab ozogamicin |b real-life data from the AMLCG, SAL, and CELL study groups |c Ricarda Knabe, Philippe Muller, Christoph Schliemann, Maher Hanoun, Julia Marie Unglaub, Barbora Weinbergerová, Jiří Mayer, Carolin Krekeler, Stefan W. Krause, Martin Kaufmann, Sabrina Kraus, Björn Steffen, Franziska Modemann, Marion Subklewe, Veit Bücklein, Wolfgang G. Kunz, Martina Rudelius, Michael von Bergwelt-Baildon, Katja Gutmair, Eva Hoster, Tobias Herold, Christoph Röllig, and Karsten Spiekermann |
| 264 | 1 | |c July 8 2025 | |
| 300 | |a 4 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 30. Juni 2025 | ||
| 500 | |a Gesehen am 26.11.2025 | ||
| 520 | |a TO THE EDITOR:The CD33-directed antibody-drug-conjugate “gemtuzumab ozogamicin” (GO) in combination with the 7+3 standard regimen is currently approved for the treatment of CD33+ acute myeloid leukemia (AML). Although the pivotal ALFA-0701 study did not show a significantly increased toxicity using 7+3 + GO compared with 7+3,1 a slightly higher rate of severe gastrointestinal (GI) toxicity was reported (16% vs 10%), and additional evidence of GO-associated GI toxicity was published.2,3 We observed several cases of severe GI toxicity and therefore analyzed patients treated with GO in a real-world setting. | ||
| 700 | 1 | |a Muller, Philippe |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schliemann, Christoph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hanoun, Maher |e VerfasserIn |4 aut | |
| 700 | 1 | |a Unglaub, Julia Marie |e VerfasserIn |0 (DE-588)1247235157 |0 (DE-627)1780861508 |4 aut | |
| 700 | 1 | |a Weinbergerová, Barbora |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mayer, Jiří |e VerfasserIn |4 aut | |
| 700 | 1 | |a Krekeler, Carolin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Krause, Stefan W. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kaufmann, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kraus, Sabrina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Steffen, Björn |e VerfasserIn |4 aut | |
| 700 | 1 | |a Modemann, Franziska |e VerfasserIn |4 aut | |
| 700 | 1 | |a Subklewe, Marion |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bücklein, Veit |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kunz, Wolfgang G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rudelius, Martina |e VerfasserIn |4 aut | |
| 700 | 1 | |a von Bergwelt-Baildon, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gutmair, Katja |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hoster, Eva |e VerfasserIn |4 aut | |
| 700 | 1 | |a Herold, Tobias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Röllig, Christoph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Spiekermann, Karsten |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood advances |d Washington, DC : American Society of Hematology, 2016 |g 9(2025), 13 vom: Juli, Seite 3336-3339 |h Online-Ressource |w (DE-627)873588312 |w (DE-600)2876449-3 |w (DE-576)48043249X |x 2473-9537 |7 nnas |a Gastrointestinal toxicity of gemtuzumab ozogamicin real-life data from the AMLCG, SAL, and CELL study groups |
| 773 | 1 | 8 | |g volume:9 |g year:2025 |g number:13 |g month:07 |g pages:3336-3339 |g extent:4 |a Gastrointestinal toxicity of gemtuzumab ozogamicin real-life data from the AMLCG, SAL, and CELL study groups |
| 856 | 4 | 0 | |u https://doi.org/10.1182/bloodadvances.2024014570 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20251126 | ||
| 993 | |a Editorial | ||
| 994 | |a 2025 | ||
| 998 | |g 1247235157 |a Unglaub, Julia Marie |m 1247235157:Unglaub, Julia Marie |d 910000 |d 910500 |e 910000PU1247235157 |e 910500PU1247235157 |k 0/910000/ |k 1/910000/910500/ |p 5 | ||
| 999 | |a KXP-PPN1942596251 |e 4814230184 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"4 S."}],"relHost":[{"title":[{"title_sort":"Blood advances","title":"Blood advances"}],"part":{"issue":"13","pages":"3336-3339","year":"2025","extent":"4","text":"9(2025), 13 vom: Juli, Seite 3336-3339","volume":"9"},"pubHistory":["Vol. 1, iss. 1 (November 2016)-"],"recId":"873588312","language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Gastrointestinal toxicity of gemtuzumab ozogamicin real-life data from the AMLCG, SAL, and CELL study groupsBlood advances","note":["Gesehen am 27.04.21"],"id":{"issn":["2473-9537"],"eki":["873588312"],"zdb":["2876449-3"]},"origin":[{"dateIssuedDisp":"[2016]-","publisher":"American Society of Hematology","publisherPlace":"Washington, DC"}],"name":{"displayForm":["American Society of Hematology"]},"physDesc":[{"extent":"Online-Ressource"}]}],"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"July 8 2025"}],"id":{"doi":["10.1182/bloodadvances.2024014570"],"eki":["1942596251"]},"name":{"displayForm":["Ricarda Knabe, Philippe Muller, Christoph Schliemann, Maher Hanoun, Julia Marie Unglaub, Barbora Weinbergerová, Jiří Mayer, Carolin Krekeler, Stefan W. Krause, Martin Kaufmann, Sabrina Kraus, Björn Steffen, Franziska Modemann, Marion Subklewe, Veit Bücklein, Wolfgang G. Kunz, Martina Rudelius, Michael von Bergwelt-Baildon, Katja Gutmair, Eva Hoster, Tobias Herold, Christoph Röllig, and Karsten Spiekermann"]},"note":["Online veröffentlicht: 30. Juni 2025","Gesehen am 26.11.2025"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"recId":"1942596251","title":[{"title_sort":"Gastrointestinal toxicity of gemtuzumab ozogamicin","title":"Gastrointestinal toxicity of gemtuzumab ozogamicin","subtitle":"real-life data from the AMLCG, SAL, and CELL study groups"}],"person":[{"given":"Ricarda","family":"Knabe","role":"aut","roleDisplay":"VerfasserIn","display":"Knabe, Ricarda"},{"given":"Philippe","family":"Muller","role":"aut","roleDisplay":"VerfasserIn","display":"Muller, Philippe"},{"role":"aut","display":"Schliemann, Christoph","roleDisplay":"VerfasserIn","given":"Christoph","family":"Schliemann"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Hanoun, Maher","given":"Maher","family":"Hanoun"},{"given":"Julia Marie","family":"Unglaub","role":"aut","display":"Unglaub, Julia Marie","roleDisplay":"VerfasserIn"},{"given":"Barbora","family":"Weinbergerová","role":"aut","roleDisplay":"VerfasserIn","display":"Weinbergerová, Barbora"},{"family":"Mayer","given":"Jiří","roleDisplay":"VerfasserIn","display":"Mayer, Jiří","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Krekeler, Carolin","role":"aut","family":"Krekeler","given":"Carolin"},{"given":"Stefan W.","family":"Krause","role":"aut","roleDisplay":"VerfasserIn","display":"Krause, Stefan W."},{"role":"aut","roleDisplay":"VerfasserIn","display":"Kaufmann, Martin","given":"Martin","family":"Kaufmann"},{"display":"Kraus, Sabrina","roleDisplay":"VerfasserIn","role":"aut","family":"Kraus","given":"Sabrina"},{"family":"Steffen","given":"Björn","display":"Steffen, Björn","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Modemann, Franziska","given":"Franziska","family":"Modemann"},{"given":"Marion","family":"Subklewe","role":"aut","display":"Subklewe, Marion","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","display":"Bücklein, Veit","role":"aut","family":"Bücklein","given":"Veit"},{"given":"Wolfgang G.","family":"Kunz","role":"aut","roleDisplay":"VerfasserIn","display":"Kunz, Wolfgang G."},{"family":"Rudelius","given":"Martina","display":"Rudelius, Martina","roleDisplay":"VerfasserIn","role":"aut"},{"display":"von Bergwelt-Baildon, Michael","roleDisplay":"VerfasserIn","role":"aut","family":"von Bergwelt-Baildon","given":"Michael"},{"given":"Katja","family":"Gutmair","role":"aut","roleDisplay":"VerfasserIn","display":"Gutmair, Katja"},{"roleDisplay":"VerfasserIn","display":"Hoster, Eva","role":"aut","family":"Hoster","given":"Eva"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Herold, Tobias","given":"Tobias","family":"Herold"},{"family":"Röllig","given":"Christoph","display":"Röllig, Christoph","roleDisplay":"VerfasserIn","role":"aut"},{"given":"Karsten","family":"Spiekermann","role":"aut","roleDisplay":"VerfasserIn","display":"Spiekermann, Karsten"}]} | ||
| SRT | |a KNABERICARGASTROINTE8202 | ||